Early-stage resectable non-small cell lung cancer in Hungary
This study provides a comprehensive analysis of early-stage resectable non-small cell lung cancer (NSCLC) in Hungary, investigating incidence rates, demographic trends, treatment patterns and survival outcomes. We used data from the National Health Insurance Fund (NHIF) spanning 2013–2022, and we an...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Pathology and Oncology Research |
| Subjects: | |
| Online Access: | https://www.por-journal.com/articles/10.3389/pore.2025.1612152/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849701241908625408 |
|---|---|
| author | Gabriella Gálffy Réka Hécz Réka Bujdosó Eszter Gáspár Réka Korompay Judit Hoffer Szilvia Szécsényi Celia Blasszauer Dániel Reibl Erika Tóth Krisztina Bogos László Agócs László Agócs Ferenc Rényi-Vámos Ferenc Rényi-Vámos Éva Mórocz |
| author_facet | Gabriella Gálffy Réka Hécz Réka Bujdosó Eszter Gáspár Réka Korompay Judit Hoffer Szilvia Szécsényi Celia Blasszauer Dániel Reibl Erika Tóth Krisztina Bogos László Agócs László Agócs Ferenc Rényi-Vámos Ferenc Rényi-Vámos Éva Mórocz |
| author_sort | Gabriella Gálffy |
| collection | DOAJ |
| description | This study provides a comprehensive analysis of early-stage resectable non-small cell lung cancer (NSCLC) in Hungary, investigating incidence rates, demographic trends, treatment patterns and survival outcomes. We used data from the National Health Insurance Fund (NHIF) spanning 2013–2022, and we analyzed 6,571 patients with available NSCLC histology and no metastasis, who underwent curative surgery within 6 months of diagnosis, and evaluated epidemiological trends and the use of neoadjuvant and adjuvant therapies. For the efficacy analysis, we narrowed the patient cohort to 5,494 patients diagnosed and treated between 2013 and 2019 with at least three-year follow-up data. Key endpoints included overall survival (OS) and disease-free survival (DFS), inferred via time to first subsequent therapy (TFST). Our results revealed a gradual decline in early-stage resectable NSCLC diagnoses, with a significant drop in 2020, likely linked to COVID-19 restrictions. Older age groups (66–75 years) represented a growing proportion of cases, reflecting shifting demographic trends. Among patients with EGFR mutations receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, OS significantly improved compared to those not receiving EGFR-TKI therapy, who are assumed to have wild-type EGFR status (HR = 0.58 (95% CI: 0.47–0.72), p < 0.0001). These findings underscore the importance of early detection, comprehensive biomarker testing and targeted therapies in improving outcomes for resectable NSCLC patients. Future studies with extended follow-up and integration of broader clinical data, including staging and patient comorbidities, are warranted to optimize therapeutic strategies. |
| format | Article |
| id | doaj-art-0e967fcd970b4c3cbc403e5426bfd508 |
| institution | DOAJ |
| issn | 1532-2807 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Pathology and Oncology Research |
| spelling | doaj-art-0e967fcd970b4c3cbc403e5426bfd5082025-08-20T03:18:01ZengFrontiers Media S.A.Pathology and Oncology Research1532-28072025-07-013110.3389/pore.2025.16121521612152Early-stage resectable non-small cell lung cancer in HungaryGabriella Gálffy0Réka Hécz1Réka Bujdosó2Eszter Gáspár3Réka Korompay4Judit Hoffer5Szilvia Szécsényi6Celia Blasszauer7Dániel Reibl8Erika Tóth9Krisztina Bogos10László Agócs11László Agócs12Ferenc Rényi-Vámos13Ferenc Rényi-Vámos14Éva Mórocz15Department of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, HungaryDepartment of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, HungaryDepartment of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, HungaryDepartment of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, HungaryDepartment of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, HungaryAstraZeneca Ltd., Budapest, HungaryAstraZeneca Ltd., Budapest, HungaryMedicalScan Ltd., Budapest, HungaryMedicalScan Ltd., Budapest, HungaryDepartment of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, HungaryNational Korányi Institute of Pulmonology, Budapest, HungaryDepartment of Thoracic Surgery, Semmelweis University, Budapest, HungaryDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, HungaryDepartment of Thoracic Surgery, Semmelweis University, Budapest, HungaryDepartment of Thoracic Surgery, National Institute of Oncology, Budapest, HungaryDepartment of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, HungaryThis study provides a comprehensive analysis of early-stage resectable non-small cell lung cancer (NSCLC) in Hungary, investigating incidence rates, demographic trends, treatment patterns and survival outcomes. We used data from the National Health Insurance Fund (NHIF) spanning 2013–2022, and we analyzed 6,571 patients with available NSCLC histology and no metastasis, who underwent curative surgery within 6 months of diagnosis, and evaluated epidemiological trends and the use of neoadjuvant and adjuvant therapies. For the efficacy analysis, we narrowed the patient cohort to 5,494 patients diagnosed and treated between 2013 and 2019 with at least three-year follow-up data. Key endpoints included overall survival (OS) and disease-free survival (DFS), inferred via time to first subsequent therapy (TFST). Our results revealed a gradual decline in early-stage resectable NSCLC diagnoses, with a significant drop in 2020, likely linked to COVID-19 restrictions. Older age groups (66–75 years) represented a growing proportion of cases, reflecting shifting demographic trends. Among patients with EGFR mutations receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, OS significantly improved compared to those not receiving EGFR-TKI therapy, who are assumed to have wild-type EGFR status (HR = 0.58 (95% CI: 0.47–0.72), p < 0.0001). These findings underscore the importance of early detection, comprehensive biomarker testing and targeted therapies in improving outcomes for resectable NSCLC patients. Future studies with extended follow-up and integration of broader clinical data, including staging and patient comorbidities, are warranted to optimize therapeutic strategies.https://www.por-journal.com/articles/10.3389/pore.2025.1612152/fullnon-small cell lung cancer (NSCLC)epidemiologyearly stagecurative surgeryEGFR mutation |
| spellingShingle | Gabriella Gálffy Réka Hécz Réka Bujdosó Eszter Gáspár Réka Korompay Judit Hoffer Szilvia Szécsényi Celia Blasszauer Dániel Reibl Erika Tóth Krisztina Bogos László Agócs László Agócs Ferenc Rényi-Vámos Ferenc Rényi-Vámos Éva Mórocz Early-stage resectable non-small cell lung cancer in Hungary Pathology and Oncology Research non-small cell lung cancer (NSCLC) epidemiology early stage curative surgery EGFR mutation |
| title | Early-stage resectable non-small cell lung cancer in Hungary |
| title_full | Early-stage resectable non-small cell lung cancer in Hungary |
| title_fullStr | Early-stage resectable non-small cell lung cancer in Hungary |
| title_full_unstemmed | Early-stage resectable non-small cell lung cancer in Hungary |
| title_short | Early-stage resectable non-small cell lung cancer in Hungary |
| title_sort | early stage resectable non small cell lung cancer in hungary |
| topic | non-small cell lung cancer (NSCLC) epidemiology early stage curative surgery EGFR mutation |
| url | https://www.por-journal.com/articles/10.3389/pore.2025.1612152/full |
| work_keys_str_mv | AT gabriellagalffy earlystageresectablenonsmallcelllungcancerinhungary AT rekahecz earlystageresectablenonsmallcelllungcancerinhungary AT rekabujdoso earlystageresectablenonsmallcelllungcancerinhungary AT esztergaspar earlystageresectablenonsmallcelllungcancerinhungary AT rekakorompay earlystageresectablenonsmallcelllungcancerinhungary AT judithoffer earlystageresectablenonsmallcelllungcancerinhungary AT szilviaszecsenyi earlystageresectablenonsmallcelllungcancerinhungary AT celiablasszauer earlystageresectablenonsmallcelllungcancerinhungary AT danielreibl earlystageresectablenonsmallcelllungcancerinhungary AT erikatoth earlystageresectablenonsmallcelllungcancerinhungary AT krisztinabogos earlystageresectablenonsmallcelllungcancerinhungary AT laszloagocs earlystageresectablenonsmallcelllungcancerinhungary AT laszloagocs earlystageresectablenonsmallcelllungcancerinhungary AT ferencrenyivamos earlystageresectablenonsmallcelllungcancerinhungary AT ferencrenyivamos earlystageresectablenonsmallcelllungcancerinhungary AT evamorocz earlystageresectablenonsmallcelllungcancerinhungary |